Clinical trial to test cancer vaccine in pet dogs | APA says FDA is ending primate study before finishing promised review | Sooty mangabey genome yields clues to how AIDS develops
January 10, 2018
FBR Smartbrief
Top Stories
Clinical trial to test cancer vaccine in pet dogs
Clinical trial to test cancer vaccine in pet dogs
(Charles McQuillan/Getty Images)
A $6.4 million grant from the Open Philanthropy Project will support a clinical trial at Colorado State University's Flint Animal Cancer Center of a vaccine to prevent any type of cancer in dogs. The trial will involve some 800 middle-aged, healthy pet dogs testing the effects of a multivalent frameshift peptide developed at Arizona State University that has shown promise in mouse studies, and scientists think the vaccine has potential for human use, too.
Arizona State University (1/3) 
LinkedIn Twitter Facebook Google+ Email
APA says FDA is ending primate study before finishing promised review
The FDA appears to be ending a study of nicotine addiction before its completion and before reviewing and reporting on the safety of the monkeys involved in the study and the integrity of the animal research process, as the agency had promised to do. The American Psychological Association asked the FDA for an update and noted that the agency "is preparing to transfer the study animals to new locations, some of which may not ensure adequate protections."
Speaking of Research (1/6) 
LinkedIn Twitter Facebook Google+ Email
Research Breakthroughs
Sooty mangabey genome yields clues to how AIDS develops
Researchers report in Nature that they sequenced the genome of the sooty mangabey and compared it with genomes from other nonhuman primates and humans to explore factors that influence susceptibility to AIDS. Simian immunodeficiency virus in sooty mangabeys is nonpathogenic, and variants at two loci may explain why SIV does not progress to AIDS in mangabeys. The findings might lead to better treatments or a vaccine.
GenomeWeb Daily News (free registration) (1/3) 
LinkedIn Twitter Facebook Google+ Email
Human antibodies generated in cows promising for MERS treatment
Human antibodies generated in cows promising for MERS treatment
(Pascal Pavani/AFP/Getty Images)
An early-stage clinical trial discussed in the journal Lancet Infectious Diseases found that human antibodies generated in genetically engineered cows were safe, and scientists say they show promise for treatment of Middle Eastern respiratory syndrome. The approach could dramatically reduce the time needed to create antibody treatments, as the process using human donors is slow and often small-scale, said John Beigel, who co-authored the study.
Reuters (1/9) 
LinkedIn Twitter Facebook Google+ Email
Dehydrated heart valves implanted in sheep
Scientists transplanted previously freeze-dried, rehydrated heart valves in live sheep, and it's possible the method could be used for the esophagus, bladder, liver and other simple organs. The method, described in Acta Biomaterialia, involved stripping cells from a piece of heart valve, soaking it in a sugary solution to preserve it and freeze-drying, then rehydrating the valve about 24 hours before it is needed.
IFLScience (UK) (1/9) 
LinkedIn Twitter Facebook Google+ Email
Novel drug delivery system could help HIV patients, swine study suggests
A novel capsule that contains a drug-laden scaffold effectively delivered three antiretroviral drugs in pigs, and a weekly oral HIV treatment could be on the horizon if human clinical trials are successful, researchers reported in Nature Communications. As the capsule dissolves, an asterisk-shaped scaffold unfolds and slowly releases drugs before breaking down and passing through the body, and the researchers say the device could be used to treat other chronic conditions.
National Public Radio (1/9),  BBC (1/9) 
LinkedIn Twitter Facebook Google+ Email
Other News
Animal Health
Veterinary college testing therapies for IBD, cancer, anxiety
Veterinary college testing therapies for IBD, cancer, anxiety
(Vyacheslav Oseledko/AFP/Getty Images)
Researchers at the University of Guelph's Ontario Veterinary College are studying whether fecal transplants can improve the symptoms of inflammatory bowel disease in dogs. Other projects underway include a study exploring the effect of stem cell therapy on surgical outcomes in dogs that with spinal cord injuries, a study using Newcastle disease virus to treat feline and canine cancers, research on whether oral sedatives can calm anxious cats during travel and veterinary exams, and a study of tarantula blood cells.
The Burlington Post (Ontario) (1/4) 
LinkedIn Twitter Facebook Google+ Email
Other News
Research News
AALAS accepting applications for grants
The American Association for Laboratory Animal Science is accepting grant applications until Feb. 1 for research designed to enhance scientific knowledge in laboratory animal health and welfare. The AALAS awards small grants of up to $7,500 and standard grants of up to $50,000.
JAVMA News (1/3) 
LinkedIn Twitter Facebook Google+ Email
FBR News
Donate to FBR
For 35 years, FBR has advanced biomedical research for the sake of both human and animal health. We can't do our job without your support. Please give what you can. Together we will continue to make a difference.
LinkedIn Twitter Facebook Google+ Email
The art of being wise is the art of knowing what to overlook.
William James,
philosopher and psychologist
LinkedIn Twitter Facebook Google+ Email
Learn more about FBR:
About FBR | Donate
About FBR
The Foundation for Biomedical Research (FBR) is the nation’s oldest and largest non-profit dedicated to improving human and animal health by promoting public understanding and support for biomedical research. Our mission is to educate people about the essential role animal research plays in the quest for medical advancements, treatments and cures for both people and animals.
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information